Information  X 
Enter a valid email address
  Print          More announcements

Wednesday 17 March, 2021

T.Rowe Price Assoc

Form 8.3 - Willis Towers Watson Plc

RNS Number : 5925S
T.Rowe Price Associates
17 March 2021
 

Ap19

FORM   8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY   INFORMATION

 

Nameofpersondealing (Note 1)

 T. ROWE PRICE ASSOCIATES, INC.

Companydealtin

 WILLIS TOWERS WATSON PLC

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 2)

 ISIN: IE00BDB6Q211

 

of dealing

  16 March 2021

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   3)

 

Long

 

 

 

(1)Relevantsecurities

2,287,754  1.77%

 

Derivatives than options)

 

 

(3)Optionsandagreementstopurchase/sell

 

 

Total

2,287,754*  1.77%

 

             

*The change in the holding of 8 shares since the last disclosure on 16 March 2021 is due to the transfer of shares into our discretionary holding

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in  (Note   3)

Classofrelevantsecurity:

Long

Short

 

 

 

(1)Relevantsecurities

 

 

 

Derivatives than options)

 

 

 

(3)Optionsandagreementstopurchase/sell

 

 

Total

 

 

             

 

Ap20

 

 

1.  DEALINGS  (Note   4)

 

(a)  Purchases and sales

 

 

Purchase/sale

 

Numberofrelevantsecurities

 

Priceperunit 5)

Purchase

Sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

391

1,013

193

221.397 USD

220.437 USD

222.100 USD

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

CFD

Natureoftransaction

6)

Numberofrelevantsecurities

7)

Priceperunit

5)

 

 

 

 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing, selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 5)

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Productname,

call option

Numberofsecurities

Exercisepriceper unit (Note 5)

 

 

 

 

(d)  Other dealings (including transactions in respect of new securities) (Note 4)

 

of transaction

8)

per unit

 

 

 

 

Ap21

 

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any 

other person relating to the voting rights of any relevant securities under any option referred to on this 

form   or   relating   to   the   voting   rights   or   future   acquisition   or   disposal   of   any  relevant securities to which 

any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

Is a Supplemental Form 8 attached?  (Note   9)    NO

 

Dateofdisclosure

 17 March 2021

Contact name

 Gary Greb

Telephone number

 001 410 345 2527

If aconnectedEFM,nameofofferee/offerorwithwhichconnected

 

If aconnectedEFM,statenatureofconnection (Note 10)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISESFFFEWEFSESD

a d v e r t i s e m e n t